Medication info
Nesinamet Tablet 12.5/1000 mg (Alogliptin Benzoate, Metformin Hydrochloride)

Nesinamet Tablet 12.5/1000 mg (Alogliptin Benzoate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Alogliptin Benzoate›17mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
Pale yellow oblong film-coated tablet
Packaging
Blister - 28 tablets/Alu-Alu[(7 X 4)], Bottle - 30 tablets/bottle[(bottle-HDPE, cap-PP, silica gel)], Bottle - 100 tablets/bottle[(bottle-HDPE, cap-PP, silica gel)]
Approval status
Active

MFDS item code 202303457 · Approved 2023.12.28 · Insurance code 693903830

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be adjusted according to efficacy and tolerability without exceeding the maximum recommended daily doses of each component: alogliptin 25mg and metformin 2000mg. The starting dose of this medicine should be determined according to the patient's current treatment regimen. To reduce gastrointestinal adverse reactions associated with metformin use, take this medicine twice daily with meals, and increase the dose gradually. Swallow this medicine whole. 1. Patients not currently receiving metformin The starting dose is 1 tablet of this medicine 12.5/500mg twice daily; the dose may be increased up to 1 tablet of this medicine 12.5/1000mg twice daily. 2. Patients who cannot achieve adequate glycemic control with metformin monotherapy The starting dose of this medicine is alogliptin 12.5mg twice daily (total daily dose 25mg) and the patient's current metformin dose, according to the patient's current treatment regimen. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and pioglitazone The starting dose of this medicine is alogliptin 12.5mg twice daily (total daily dose 25mg), and the starting dose of metformin should be determined based on the patient's blood glucose level and current dose. 4. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and insulin The starting dose of this medicine is alogliptin 12.5mg twice daily (total daily dose 25mg), and the starting dose of metformin should be determined based on the patient's blood glucose level and current dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. 5. Substitution for combination therapy with alogliptin and metformin When switching from combination therapy with alogliptin and metformin to this medicine, treatment may be started at the current doses of alogliptin and metformin.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

View approved original text

This medication helps to manage blood glucose levels in patients with type 2 diabetes by using alogliptin and metformin together. Effective blood sugar control can be achieved when this medication is used in conjunction with diet and exercise treatment. Therefore, this medication is used to improve blood glucose control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be adjusted according to efficacy and tolerability without exceeding the maximum recommended daily doses of each component: alogliptin 25mg and metformin 2000mg. The starting dose of this medicine should be determined according to the patient's current treatment regimen. To reduce gastrointestinal adverse reactions associated with metformin use, take this medicine twice daily with meals, and increase the dose gradually. Swallow this medicine whole. 1. Patients not currently receiving metformin The starting dose is 1 tablet of this medicine 12.5/500mg twice daily; the dose may be increased up to 1 tablet of this medicine 12.5/1000mg twice daily. 2. Patients who cannot achieve adequate glycemic control with metformin monotherapy The starting dose of this medicine is alogliptin 12.5mg twice daily (total daily dose 25mg) and the patient's current metformin dose, according to the patient's current treatment regimen. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and pioglitazone The starting dose of this medicine is alogliptin 12.5mg twice daily (total daily dose 25mg), and the starting dose of metformin should be determined based on the patient's blood glucose level and current dose. 4. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and insulin The starting dose of this medicine is alogliptin 12.5mg twice daily (total daily dose 25mg), and the starting dose of metformin should be determined based on the patient's blood glucose level and current dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. 5. Substitution for combination therapy with alogliptin and metformin When switching from combination therapy with alogliptin and metformin to this medicine, treatment may be started at the current doses of alogliptin and metformin.

Precautions

This medication contains metformin hydrochloride and alogliptin benzoate as the main components and is used to control blood sugar levels. Care should be taken when taking this medication as severe lactic acidosis or hypoglycemia may occur. Lactic acidosis is a rare but potentially fatal metabolic complication that can be more likely to occur during sudden kidney function decline, cardiopulmonary diseases, or infections. This medication should not be administered to certain patients. For example, it should not be taken by individuals who are hypersensitive to alogliptin or metformin, or those with severe kidney impairment, heart failure, acute myocardial infarction, or sepsis. Additionally, the use of radiocontrast iodine tests can affect kidney function, so this medication should be temporarily discontinued before and after the tests, and should only be resumed after kidney function is confirmed to be normal. Caution is also required for pregnant or breastfeeding women, patients with severe liver dysfunction, severe infections, and pre- or post-surgical patients when taking this medication. This medication may cause side effects such as gastrointestinal disturbances, headaches, infections, and hypoglycemia, and especially hypoglycemia symptoms should be closely monitored. The risk of hypoglycemia is higher during irregular meals, excessive exercise, or when combined with other hypoglycemic agents. Symptoms of lactic acidosis include fatigue, muscle pain, difficulty in breathing, and abdominal pain, so these symptoms should prompt immediate consultation with a physician. Regular liver and kidney function checks should be conducted, and caution should be heightened particularly for the elderly or patients with impaired renal function. Furthermore, alcohol consumption can increase the risk of lactic acidosis, so it is advisable to avoid drinking alcohol. There may be interactions with other medications while taking this medication, so if other medications are being taken, it is essential to inform the doctor or pharmacist. Rare side effects such as bullous pemphigoid or severe arthralgia may occur, so if there are any skin abnormalities or severe joint pain, immediate notification to the medical staff is necessary. Finally, the safety and efficacy of this medication in pediatric patients have not been established, so it should not be used in children.

Side effects

Upper respiratory tract infection, nasopharyngitis, diarrhea, hypertension, headache, back pain, urinary tract infection, hypoglycemia, pancreatitis, hypersensitivity, serum sickness, nausea, vomiting, bloating, asthenia, dyspepsia, abdominal discomfort, tendinitis, fracture, costochondritis, leg fracture, upper limb fracture, spinal fracture, rhabdomyolysis, acute pancreatitis, gastric ulcer, exacerbation of gastritis, hemorrhagic gastric ulcer, appendicitis, abscess, infection, wound dehiscence, thyroid carcinoma, lung cancer, pulmonary neoplasm, chest discomfort, generalized edema, generalized weakness, dyspnea, exacerbation of asthma, exacerbation of pneumonia, respiratory arrest, acute renal failure, kidney stones, renal dysfunction, liver cirrhosis, cholelithiasis, myocardial infarction, angina, anorexia, cerebral infarction, transient ischemic attack, laceration, exacerbation of atrial fibrillation, speech disorder, stomatitis, abdominal pain, gastroesophageal reflux, gastroesophageal reflux disease, gastrointestinal disorder, atrophic gastritis, non-specific epigastric pain unrelated to food, periodontitis, toothache, belching, anal fissure, blood in stool, melena, constipation, nausea, vomiting, cough, increased phlegm, bronchial spasm, dry cough, chronic obstructive pulmonary disease, throat irritation, sinusitis, shortness of breath, sore throat, tonsillitis, vitamin D deficiency, increased triglycerides, increased CPK, hypertriglyceridemia, hyperkalemia, acidosis, dry eye syndrome, gout, elevated blood glucose levels, diabetic retinopathy, cystitis, exacerbation of cystitis, frequent urination, neurogenic bladder, urethritis, hematuria, elevated serum creatinine, unspecified abnormalities in liver function tests, biliary sclerosis, fatty liver, increased AST, increased ALT, herpes zoster, herpes labialis, herpes virus infection, prostate enlargement, benign prostatic hyperplasia, depression, hypersensitivity, erectile dysfunction, insomnia, sleep disorder, orthostatic hypotension, hypotension, tinnitus, acute hearing loss, Meniere's disease, cataract extraction, bradycardia, palpitations, atherosclerosis, hypothyroidism, nodular thyroid disease, pruritus, skin tingling, sensory disturbances, femoral sensory neuropathy, fecal incontinence, tremors, numbness, neuropathic pain, spinal stenosis, hemiplegia, skin sensory disturbances, dizziness, vertigo, ligament injury, joint pain, fibromyalgia, muscle cramps, myalgia, leg weakness, malaise, trigger finger syndrome, plantar fasciitis, tendon rupture, arthrosis, malaise, pruritus, contact dermatitis, keratosis, sclerosis, increased sweating, nail disease, otitis externa, pityriasis rosea, rosacea, contact dermatitis, furunculosis, seborrheic dermatitis, conjunctivitis, glaucoma, macular degeneration, cataract, keratitis, retinal disease, retinal disorder, retinal disease, increased blood glucose, hyperlipidemia, diabetes complications, exacerbation of diabetes, dyslipidemia, increased triglycerides, chest pain, back pain, brain disorder, neck and shoulder pain, skin cyst, atrial fibrillation, neurogenic bladder

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture ingress. Additionally, the medication should be kept away from areas that are too hot or too cold, preferably stored at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow oblong film-coated tablet

Package unit

Blister - 28 tablets/Alu-Alu[(7 X 4)], Bottle - 30 tablets/bottle[(bottle-HDPE, cap-PP, silica gel)], Bottle - 100 tablets/bottle[(bottle-HDPE, cap-PP, silica gel)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.